Advertisement

Using Patient Advisory Boards to Solicit Input Into Clinical Trial Design and Execution

  • Annick Anderson
    Correspondence
    Address correspondence to: Annick Anderson, MBA, Research Services, Center for information and Study on Clinical Research Participation, One Liberty Square, Suite 1100, Boston, MA 02110, USA.
    Affiliations
    Center for Information and Study on Clinical Research Participation, Tufts University School of Medicine, Boston, MA, USA
    Search for articles by this author
  • Jasmine Benger
    Affiliations
    Center for Information and Study on Clinical Research Participation, Tufts University School of Medicine, Boston, MA, USA
    Search for articles by this author
  • Ken Getz
    Affiliations
    Center for Information and Study on Clinical Research Participation, Tufts University School of Medicine, Boston, MA, USA
    Search for articles by this author

      Abstract

      Academic institutions, pharmaceutical and biotechnology companies, foundations, and associations are routinely implementing patient advisory boards (PABs) to solicit patients' voices and perspectives on a variety of clinical research–related areas, including protocol design, clinical trial execution, informed-consent form design, clinical trial medicine kit design, wearable devices and mobile technologies, and patient-communication materials. Based on experience conducting >50 PABs during the past several years, the authors provide insights into how to best plan and execute PABs and their value in informing improvement in patient engagement.

      Key words

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Stergiopoulos S.
        • Michaels D.L.
        • Kunz B.L.
        • Getz K.A.
        Measuring the impact of patient engagement and patient centricity in clinical research and development.
        Ther Innov Regul Sci. 2019; (http://doi.org/10.1177/2168479018817517 [Epub ahead of print 3 Jan 2019])
        • Drug Information Association
        Patient engagement in drug development study.
        January 31, 2016
      1. Ken Getz. Presented at: 3rd Annual Patients as Partners USA Conference, March 2–3, 2017, Philadelphia, Pa.

        • Dewulf L.
        Patient engagement by pharma—why and how? A framework for compliant patient engagement.
        Ther Innov Regul Sci. 2015; 49: 9-16
        • Korieth K.
        • Anderson A.
        Novo nordisk, servier, otsuka, teva among top sponsors.
        CenterWatch Monthly Newsl. 2017; 24: 1-13
        • European Medicines Agency
        Involvement of Patient Representatives in Scientific Advice Procedures at EMA [EMA Website].
        (Available at:) (Accessed March 24, 2017)
        • Perfetto E.M.
        • Burke L.
        • Oehrlein E.M.
        • Epstein R.S.
        Patient-focused drug development.
        Med Care. 2015; 53: 9-17
        • Anderson A.
        • Getz K.
        Insights and best practices for planning and implementing patient advisory boards.
        Ther Innov Regul Sci. 2018; 52: 469-473